Silence Therapeutics received designations for its divesiran program from the FDA, leading to stock price movement.
1 report, 1 independent
Updated Aug 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Silence Therapeutics received designations for its divesiran program from the FDA, leading to stock price movement.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Silence Therapeutics
UK business
- FDA
Related events
- RedHill Biopharma's stock surged on Nasdaq following the divestment of its Talicia business to Apotex for $18M, while future products seek FDA approval.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Rocket is utilizing Nasdaq for investor evaluation and the FDA reviewed Phase 2 efficacy data for its product RP-A501.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.